Business
Japanese Patent Grant for Kinase Inhibitors
Japanese Patent Grant for Kinase Inhibitors.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 0916L Sareum Holdings PLC 02 July 2014 \n \n\n\n\n\n\n(AIM: SAR)\n\n\n2 July 2014\n\n\n\n\nSAREUM HOLDINGS PLC\n(\"Sareum\" or the \"Company\")\nJapanese Patent Grant for Sareum's Kinase Inhibitors\nSareum (AIM: SAR), the specialist cancer drug discovery and development business, is pleased to announce that the Company has been notified by the Japan Patent Office that a patent has been granted for one of Sareum's key drug discovery inventions. \nThis patent*, which relates to compounds that inhibit or modulate the activity of kinase enzymes, forms the basis of Sareum's SKIL® drug discovery platform. The granting of this patent means that Sareum has approved patent protection in the Japan for its SKIL platform and many of its drug discovery programmes. The Company expects to receive similar protection in Europe and other major markets in due course.\nSKIL (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.\n* Patent No. 5555620,\nSareum's CSO, Dr John Reader, commented: \"The granting of this patent in Japan strengthens our patent portfolio, and enhances our negotiating position with potential licensing partners\".\n\n\n\n\nEnquiries:\nSareum Holdings plc\n\n\n\n\n\n\n\nTim Mitchell\n\n\n01223 497 700\n\n\n\n\nSanlam Securities UK Limited (Nomad)\n\n\n\n\nSimon Clements / James Thomas \n\n\n020 7628 2200\n\n\n\n\nHybridan LLP (Broker)\n\n\n\n\n\n\n\nClaire Noyce / William Lynne\n\n\n0203 713 4581/ 4582\n\n\n\n\nThe Communications Portfolio (Media enquiries)\n\n\n\n\n\n\n\nAriane Comstive\[email protected]\n\n\n020 7536 2028\n\n\n\n\nNotes for editors: \nAbout Sareum Holdings plc\nSareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage. \nSareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network ...